APRE - Aprea Therapeutics Inc

https://aprea.com

Momentum: Bearish

Recent News

No recent news found.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.

52W High

$5.01

52W Low

$1.41

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.58

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.35

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

10.74

P/B (<3 favorable)

0.67

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

11.30%

Institutions (25–75% balanced)

31.20%

Shares Outstanding

5,825,300

Float

4,635,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

841,010

Gross Profit (TTM)

-8,759,752

EPS (TTM)

-2.30

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-28.68%

ROE (TTM) (>15% strong)

-0.68%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.79

Momentum

Bearish momentum

Value

-0.0435

-0.0444

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025